Advanced Enzyme Technologies Ltd.
Snapshot View

412.60 -4.20 ▼-1.0%

05 August 2021, 04:00:00 P.M.
Volume: 28,447

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.advancedenzymes.com
Financial Indicators
Market Cap 4,584.03 Cr.
Earnings per share (EPS) 13.08 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 31.35 Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 86.86 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.72 Calculated using Price: 410.10
Dividend Yield 0.15 Period Ending 2020-03
No. of Shares Subscribed 11.18 Cr. 111,778,300 Shares
FaceValue 2
Company Profile

The company was incorporated as a private limited company on March 15, 1989 under the provisions of the Companies Act, 1956 as Advanced Biochemicals Private Limited in Maharashtra. Pursuant to a special resolution passed by the shareholders of the Company at the extra-ordinary general meeting held on April 21, 1992, the Company was converted into a public limited company and consequently the name of the Company was changed to Advanced Biochemicals Limited. A fresh certificate of change of name reflecting the new name was issued by the Registrar of Companies, Maharashtra on May 28, 1992. Pursuant to a special resolution passed by the shareholders of their Company at the extra-ordinary general meeting held on August 8, 2005, the name of Company was further changed from Advanced Biochemicals Limited to Advanced Enzyme Technologies Limited. A fresh certificate of incorporation reflecting the new name was issued by the Registrar of Companies, Maharashtra, Mumbai on August 19, 2005.

Advanced Enzymes is a research driven company with global leadership in manufacturing of enzymes and probiotics. It is the largest Indian enzyme company engaged in the research and development, manufacturing and marketing of huge proprietary products developed from various indigenous enzymes & probiotics. The company’s aim is to help consumers’ access side-effect free healthcare, help farmers enhance nutrition for animals, and also to help the industry replace traditional thermal-chemical-mechanical processes into enzyme passed processes.

Business area of the company

The company is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (R&D) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-effective unique and innovative solutions, thereby enabling their customers to develop superior products and processes. The company products assist its customers in making most of their resources, optimizing their processes, improving their product quality, saving their time and money while also mitigating the impact on the environment. It supplies these value-added and eco-safe enzyme products to diverse end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although, the company has the capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, their major focus is on developing enzymes through microbial fermentation.

Products & Solutions

Human Nutrition: The company’s enzymes are being used by a wide range of customers globally as active ingredients in their pharmaceutical and nutraceutical formulations.

Animal Nutrition: By adding its enzymes to feed, the digestibility of the feed components can be enhanced considerably.

Food Processing: The company’s enzymes play an essential role in bringing more nutrition and appeal to food & beverages products, offering significant benefits beyond the scope of traditional alternatives.

Non-Food Processing: AETL offers eco-safe solutions for a variety of industries such as textiles, leather, detergent, paper & pulp which are used in manufacturing a wide range of products.

Awards

  • 2010: Advanced Enzymes receives Bio-Excellence in Industrial Biotech!
  • 2010: Advanced Enzymes wins the ‘Emerging India Awards 2010’ for Life sciences-Pharmaceuticals & Chemicals segment
  • 2011: Dr. Anil Gupta, General Manager - R&D receives the 2011 Business Leader Award from CHEMTECH foundation
  • 2012: Advanced Enzymes Technologies Limited-received most innovative exporter's award at 'ECGC organized - D&B Indian Exporters Excellence awards.
  • 2013: Advanced Enzymes ranked amongst India’s Fastest-Growing Mid-Sized Cos.
  • 2014: Advanced Enzymes receives Inc. India 500
  • 2014: Advanced Enzymes receives Bio-Excellence in Industrial Biotech
  • 2016: Advanced Enzymes Receives Best Nutraceutical Company of the Year Award
  • 2017: Best IPO Award by IR Society
  • 2018: FE CFO Awards 2018

History and Milestones

  • 1958: Mr. L.C. Rathi sets up India's first enzyme manufacturing plant.
  • 1978: Mr. L.C. Rathi pioneered the production of an enzyme called Papain.
  • 1986L: Acquisition of Super Organic Research Laboratories (SORL) to begin extraction of several commercial enzymes.
  • 1989: Establishment of Rathi Papains Pvt. Ltd. with Mr. L.C.Rathi and Mrs. Savita Rathi as it's founding directors.
  • 1989: Advanced Biochemicals Private Ltd is incorporated to offer global and holistic enzyme solutions.
  • 1991: Advanced Biochemicals commissioned its first fermentation facility at Sinnar, Maharashtra
  • 1992: Advanced Biochemicals is converted from a private company to a public company and renamed as Advanced Biochemicals Limited
  • 1993: Advanced Biochemicals sets up fermentation-based enzyme manufacturing plant with the help of foreign collaboration.
  • 1994: SORL is merged with Advanced Biochemicals Ltd
  • 1996: Advanced Biochemicals sets up a dedicated Application Research facility.
  • 1997: Advanced Biochemicals turns around and reports its first profits.
  • 2001: Advanced Biochemicals' in-house R&D labs at Thane and Sinnar are recognized by the Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology, Government of India.
  • 2003: Sinnar Factory receives ISO 9001:2000 Systems certification.
  • 2004: Advanced Biochemicals is ranked as the largest domestic manufacturer of Industrial Enzymes.
    Advanced Biochemicals files its first patent.
  • 2005: Advanced Biochemicals Limited is renamed as Advanced Enzyme Technologies Limited (or Advanced Enzymes).
  • 2005: Sinnar Factory receives WHO CGMP certification.
  • 2006: Advanced Enzymes acquires 10 Acre land at Pitampur SEZ near Indore to setup state-of-the-art export oriented facility.
  • 2007: Phase I of the export oriented fermentation facility is completed at Pitampur SEZ near Indore.
  • 2008: Advanced Enzytech Solutions Ltd (Enzytech) is established as a subsidiary of Advanced Enzymes to cover non-food processing divisions.
  • 2009: Advanced Enzyme Far East Ltd., a subsidiary of Advanced Enzymes is dedicated to serving the Chinese market.
  • 2010: Advanced Enzymes is honoured with the 'Emerging India Awards 2010' for Life Science - Pharmaceuticals & Chemicals segment organized by ICICI Business Banking and CNBC TV18.
  • 2010: Advanced Enzymes receives the Bio-Excellence 2010 award as the Best Industrial Biotech Company of the year by the department of IT-BT & ST, Govt. of Karnataka.
  • 2011: Advanced Enzymes expands its presence in the US with the takeover of Cal India Foods International (Specialty Enzymes and Biotechnologies) as a step down subsidiary.
  • 2012: Advanced Enzymes consolidates it presence in the US with the take over of Advanced Supplementary Technologies Corporation as a step down subsidiary.
  • 2012: Advanced Enzymes is awarded 1st runner-up as the Most Innovative Exporter by ECGC - D&B Indian Exporters' Excellence Awards 2012.
  • 2012: Phase II of fermentation facility is inaugurated at Pitampur SEZ near Indore.
  • 2012: Advanced Enzymes receives its first US patent.
  • 2013: Advanced Enzymes is ranked amongst the top 500 as part of Inc. India's fastest-growing mid-sized companies' list for 2012.
  • 2014: Advanced Enzymes has received the Bio-Excellence award for being the Best Industrial Biotech Company at Bangalore India Bio 2014 event - the premier Biotechnology event in the country.
  • 2014: Advanced Enzymes is ranked amongst the top 500 of India’s fastest-growing mid-sized companies list for 2013 by Inc. India.
  • 2016: Conducts IPO & lists itself on the Indian Stock Exchanges.
  • 2016: Acquires majority stake in JC Biotech.
  • 2017: Acquired 100% stake in a German based company evoxx technologies GmbH.
  • 2017: GRAS dossier was filed with USFDA
  • 2018: 4 food enzymes got approved as a processing aid with Food Safety Standard Authority of India (FSSAI)
  • 2018: 4 enzymes are registered with REACH –ECHA (European Chemical Agency)

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.01%
1 Week
+3.24%
1 Month
+0.84%
3 Month
-9.63%
6 Month
+23.37%
1 Year
+97.98%
2 Year
+172.88%
5 Year
+44.91%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 42.58 39.10 12.70 27.31 31.32 25.06 18.34 18.82 17.61
Return on Capital Employed (%) 27.73 26.71 12.25 25.49 35.68 31.53 25.88 24.96 23.21
Return on Assets (%) 13.54 13.65 5.29 12.81 17.81 18.00 14.28 15.13 14.98

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 97 163 167 212 278 464 559 679 840
Non Curr. Liab. 146 130 94 64 56 32 47 35 44
Curr. Liab. 105 100 133 131 111 65 99 65 60
Minority Int. 2 3 4 4 5 21 23 26 28
Equity & Liab. 349 396 398 412 450 583 727 805 971
Non Curr. Assets 273 302 306 307 311 440 517 523 596
Curr. Assets 77 94 92 104 140 143 211 282 376
Misc. Exp. not W/O
Total Assets 349 396 398 412 450 583 727 805 971

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 172 220 239 223 294 329 391 420 444
Other Income 3 4 2 3 1 3 3 6 6
Total Income 175 224 241 226 295 332 394 425 450
Total Expenditure -110 -130 -138 -133 -156 -178 -227 -237 -241
PBIDT 65 94 103 93 139 154 166 188 209
Interest -12 -10 -13 -9 -8 -4 -9 -5 -4
Depreciation -6 -7 -10 -9 -9 -13 -18 -21 -26
Taxation -13 -26 -7 -23 -41 -44 -45 -46 -46
Exceptional Items 0 -51 -4
PAT 34 51 21 52 77 93 94 116 133

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 88 41 56 54 93 107 116 129 141
Cash Fr. Inv. -200 -30 -9 -11 -5 -60 -78 -125 -45
Cash Fr. Finan. 100 -5 -33 -36 -63 -65 -2 -43 -39
Net Change -12 7 13 6 26 -18 36 -39 58
Cash & Cash Eqvt 5 3 2 4 25 8 61 23 83

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 57.30 57.86 57.86 57.88 58.13 55.45 55.39 55.38 52.30
Public 42.70 42.14 42.14 42.12 41.87 44.55 44.61 44.62 47.70
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Company will host a Conference call for Analysts and Investors to discuss the unaudited Financial Results of the Company for the quarter ended June 30 2021 on Monday August 09 2021 at 04:00 p.m. (IST) as per the details provided in the Annexure.
Sat, 31 Jul 2021
Closure of Trading Window
Further to our letter dated June 30 2021 intimating closure of Trading Window from July 01 2021 we wish to inform you that for the above mentioned purpose the Trading Window for dealing in the Securities of the Company shall continue to remain closed up to August 09 2021.
Sat, 31 Jul 2021
Board Meeting Intimation for Board Meeting And Closure Of Trading Window
Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2021 inter alia to consider and approve un-audited financial results (Standalone & Consolidated) of the Company for the quarter ended June 30 2021

Technical Scans View Details

Thu, 05 Aug 2021
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Closing Near 50 SMA Closing Near 50 SMA
Closing Near 100 SMA Closing Near 100 SMA
Close Crossing 50 SMA From Above Close Crossing 50 SMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%